Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 2/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2039982 | 0.84 | MAPK9 (0.42) | MAPK9MAPK10FLT3DYRK1AMAPK13 | |
| SCHEMBL2052150 | 0.84 | MAPK9 (0.42) | MAPK9MAPK10FLT3DYRK1AMAPK13 | |
| SCHEMBL84413 | 0.82 | HRH4 (0.49) | MAPK9MAPK10HTR3AHRH4MAPK8 | |
| Hydrochloric Acid SCHEMBL29243489 | 0.80 | MAPK9 (0.42) | MAPK9MAPK10FLT3DYRK1AMAPK13 | |
| SCHEMBL27903061 | 0.80 | MAPK9 (0.39) | MAPK9MAPK10FLT3DYRK1AMAPK13 | |
| SCHEMBL27903059 | 0.80 | MAPK9 (0.39) | MAPK9MAPK10FLT3MAPK14AURKA | |
| SCHEMBL84026 | 0.79 | ACACB (0.40) | HTR3APDPK1CYP2C19HRH4 | |
| SCHEMBL1800915 | 0.79 | SMN1; SMN2 (0.43) | MAPK9MAPK10FLT3DYRK1AMAPK13 | |
| SCHEMBL14002039 | 0.77 | MAPK9 (0.37) | MAPK9MAPK10HTR3ACYP3A4CYP2D6 | |
| SCHEMBL84439 | 0.77 | HRH4 (0.54) | CDC7HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-11-09 | — | — | US | disclosed |
| WO-2023108103-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. | 2023-04-20 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-7696210-B2 | Gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| US-7569589-B2 | Potassium channel inhibitors | MERCK & CO., INC. (US) | 2009-08-04 | — | — | US | disclosed |
| US-7449465-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-11 | — | — | US | disclosed |
| US-20070244138-A1 | Mercaptoimidazoles as Ccr2 Receptor Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244138-A1 | Mercaptoimidazoles as Ccr2 Receptor Antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117631-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | MAPK9 487/4885MAPK10 497/4885HTR3A 2115/4885 |
| US-20070244138-A1 | Mercaptoimidazoles as Ccr2 Receptor Antagonists | CCR2, CCR1, CCR5 | MAPK9 1784/4885MAPK10 2350/4885HTR3A 132/4885 |
| US-20230357179-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | MAPK9 201/4885MAPK10 362/4885HTR3A 4398/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | MAPK9 425/4885MAPK10 311/4885HTR3A 3347/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | MAPK9 220/4885MAPK10 223/4885HTR3A 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.